ALERT: COVID19 Update: For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patient’s protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are available for routine office visits.

All Patients – Very Important: Regardless of vaccination status.  If you are experiencing a fever or cold-like like symptoms, which also include GI Symptoms and Diarrhea, you should contact your Virginia Cancer Specialists Advice Line before visiting our clinics for scheduled appointments. This includes symptoms of respiratory illness, such as coughing or difficulty breathing.  More Information-PLEASE CLICK HERE

John Feigert, MD

VCS Physicians

John Feigert, MD Headshot

What an exciting time to be treating cancer patients! The advances in treatment over the past few years now generate tremendous optimism that you can see on our patient’s faces.

Work and Credentials:

Primary Location

Arlington Office


Medical Oncologist

Board Certification

Medical Oncology, Hematology and Internal Medicine


New York Hospital/Cornell University Medical College, Medical Oncology and Hematology


New York Hospital/Cornell University Medical College


New York Hospital/Cornell University Medical College

Medical School

Cornell University School of Medicine


Harvard College

With a specific interest in teaching, Dr. Feigert has held several instructional positions throughout his career. After earning his Medical Degree from the Cornell University School of Medicine, he spent a year as an Instructor of Medicine at the Cornell University Medical College and another year as the Medical Director of the Division of Oncology at Elliot Hospital in Manchester, New Hampshire. Dr. Feigert has also served as a Clinical Assistant Professor at Georgetown University Medical Center and at the Virginia Commonwealth University’s INOVA Fairfax campus.

Dr. Feigert has been recognized as a Top Doctor in both Northern Virginia Magazine and Washingtonian magazine. He has also been recognized by the Alpha Omega Alpha Honor Medical Society. Dr. Feigert is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology and the Arlington County Medical Society. He is actively involved in local tumor boards, and he supports international communities through his participation with the Virginia Hospital Center Medical Brigade, a volunteer organization that helps bring clean water and health care to areas in Honduras.

During his spare time, Dr. Feigert is an active tennis player.


Physician Publications

February 1, 2020

2020 Northern Virginia Magazine Top Doctors

Read More
October 1, 2015

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.

Read More
June 10, 2012

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome.

Read More

More Publications by John Feigert, MD

March 1, 2010

Oncologists’ Experience in Reporting Cancer Staging and Guideline Adherence: Lessons From the 2006 Medicare Oncology Demonstration.

Read More
November 1, 2009

Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.

Read More
November 1, 2008

Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)

Read More
November 16, 2007

Deferasirox (ICL670; Exjade) Reduces Serum Ferritin and Labile Plasma Iron in Patients with Myelodsyplastic Syndromes.

Read More
January 1, 1998

A Comparison of Efficacy of Sargramostim (yeast-derived Rhu GM-CSF) and Filgrastim (Bacteria-derived Rhu G-CSF) in the Therapeutic Setting of Chemotherapy-induced Myelosuppression.

Read More
July 1, 1997

Randomized Trial Comparing the Tolerability of Sargramostim (yeast-derived RhuGM-CSF) and Filgrastrim (Bacteria-derived RhuG-CSF) in Cancer Patients Receiving Myelosuppressive Chemotherapy.

Read More
September 1, 1996

Rapidly Progressive Prostate Cancer in the Primary Care Setting.

Read More
January 1, 1990

Multicentric Angiofollicular Lymph Node Hyperplasia with Peripheral Neuropathy, Pseudotumor Cerebri, IgA Dysproteinemia, and Thrombocytosis in Women: A Distinct Clinicopathology Entity.

Read More
January 1, 1988

Tissue Plasminogen Activator Binds to Immobilized Immunoglobulin G: Enhancement by Plasmin and the Identification of Plasmin Derived Fab as the t-PA Binding Fragment.

Read More
January 30, 1987

Porcine Factor VIII Controls Severe Bleeding in Acquired Von Willebrand's Disease By Supplying Von Willebrand's Factor.

Read More

Primary Location

Arlington Office Office

Arlington Office

Learn More

Other Locations


November 1, 2020
Washingtonian Magazine Top Doctors 2020

January 1, 2019

Northern Virginia Magazine Top Doctor 2019

January 1, 2018

2018 Washingtonian Magazine Top Doctor Nomination

January 1, 2018
Virginia Living Magazine Top Doctors 2018

Top Doctors Virginia Living Magazine 2018

January 1, 2018
Northern Virginia Magaine Top Doctor 2018

Northern Virginia Magazine Top Doctors 2018

September 9, 2016
Washingtonian Magazine

Washingtonian Top Doctor 2016

September 1, 2015
Washingtonian Magazine

Washingtonian Top Doctor 2015

February 1, 2015
Northern Virginia Magazine

Top Doctor 2015

January 31, 2014
Northern Virginia Magazine

Top Doctor 2014

December 31, 2013
Washingtonian Magazine

Top Doctor 2014